|MDACC Study No:||2012-0648 (clinicaltrials.gov NCT No: NCT02115295)|
|Title:||PHASE II STUDY OF CLADRIBINE PLUS IDARUBICIN PLUS CYTARABINE (ARAC) IN PATIENTS WITH AML, HR MDS, OR MYELOID BLAST PHASE OF CML|
|Principal Investigator:||Tapan Kadia|
|Treatment Agent:||Cladribine; Cytarabine; Idarubicin|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
cladribine, idarubicin, and cytarabine can help to control AML, high risk MDS,
and/or CML in blast phase. The safety of these drugs will also be studied.